The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

A pilot study to investigate the potential role of atosiban, a selective oxytocin receptor inhibitor, in the management of endometriosis-related pain. Ten patients will be administered atosiban intravenously during 6 hours on a day during their period when they experience (severe) pain

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University Medical Center
• Treatments: Atosiban

Criteria

Inclusion Criteria:

• Laparoscopic, MRI or ultrasound confirmed endometriosis

• Dysmenorrhea with an average pain score ≥5 on the most painful day during menstrual period or withdrawal bleeding

Exclusion Criteria:

• Inability to come to the hospital for the experiment

• Suspicion on a (post)menopausal state

• Continuous treatment with oral contraceptives or progestagens

• Current use of gonadotrophin releasing-hormone agonist

• Current ovarian stimulation

• Current breastfeeding

• Labour or breastfeeding within the last 6 weeks

• Diagnosis of chronic pelvic pain

• Inability to give informed consent

• Language barrier

• Diabetes Mellitus, type I or II

• Hypersensitivity to atosiban or mannitol

• Use of systemic betamimetics

• Use of calcium channel blockers